At the present time, the Company cannot predict the extent or duration of the impact of the COVID-19 outbreak on its operating results. The gross principal balance outstanding for the convertible senior notes was $287.5 million as of September 30, 2020. Natera's Third Quarter 2020 Financial Results Conference Call, https://edge.media-server.com/mmc/p/dpgmrrok. Weighted average shares outstanding were approximately 80.9 million in the third quarter of 2020. Subsequent events may cause these expectations to change, and Natera disclaims any obligation to update the forward-looking statements in the future. Additional risks and uncertainties that could affect our financial results are included under the captions, "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in our most recent filings on Forms 10-K and 10-Q and in other filings that we make with the SEC from time to time. Fiscal Year 2020 Outlook: As a result of the highly dynamic situation and ongoing disruptions from COVID-19, the company is withdrawing its financial guidance for the 2020 fiscal year. SAN CARLOS, Calif., Nov. 5, 2020 /PRNewswire/ — Natera, Inc. (NASDAQ:  NTRA), a pioneer and global leader in cell-free DNA testing, today reported financial results for the third quarter ended September 30, 2020 and provided an update on recent business progress. Gross margin is calculated as gross profit divided by GAAP total revenues. Natera's First Quarter 2020 Financial Results Conference Call . Total revenues were $94.0 million in the first quarter of 2020 compared to $66.8 million for the first quarter of 2019, an increase of 41%. Operating losses were generally … Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced it will present new data at the 2020 American Society of Nephrology (ASN) Kidney Week virtual meeting taking place October 22-25, 2020. Net loss for the third quarter of 2020 was $58.3 million, or ($0.72) per diluted share, compared to net loss of $23.1 million, or ($0.33) per diluted share, for the same period in 2019. First Quarter Ended March 31, 2020 Financial Results . Presented new Signatera data at the 2020 European Society for Medical Oncology. "Q3 was an exceptional quarter," said Steve Chapman, Natera's Chief Executive Officer. We also use them to share usage information with our partners. It offers proprietary genetic testing services to inform obstetricians, transplant physicians, oncologists, and cancer researchers, including biopharmaceutical companies, and genetic laboratories through its cloud-based software platform. The mission of the company is to change the management of disease worldwide with a focus on women’s health, oncology, and organ health. Natera's Third Quarter 2020 Financial Results Conference Call Date: Thursday, November 5, 2020 Time: 1:30 p.m. PT (4:30 p.m. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including: we face numerous uncertainties and challenges in achieving our financial projections and goals; we may be unable to maintain our business and operations as planned in light of the COVID-19 pandemic; we may be unable to further increase the use and adoption of Panorama and Horizon, through our direct sales efforts or through our laboratory partners, or to develop and successfully commercialize new products, including Signatera and Prospera; we have incurred losses since our inception and we anticipate that we will continue to incur losses for the foreseeable future; our quarterly results may fluctuate from period to period; our estimates of market opportunity and forecasts of market growth may prove to be inaccurate; we may be unable to compete successfully with existing or future products or services offered by our competitors; we may not be successful in commercializing our cloud-based distribution model; our products may not perform as expected; the results of our clinical studies, including our SNP-based Microdeletion and Aneuploidy RegisTry, or SMART, Study, may not be compelling to professional societies or payors as supporting the use of our tests, particularly in the average-risk pregnancy population or for microdeletions screening, or may not be able to be replicated in later studies required for regulatory approvals or clearances; if our primary CLIA-certified laboratory facility becomes inoperable, we will be unable to perform our tests and our business will be harmed; we rely on a limited number of suppliers or, in some cases, single suppliers, for some of our laboratory instruments and materials and may not be able to find replacements or immediately transition to alternative suppliers; if we are unable to successfully scale our operations, our business could suffer; the marketing, sale, and use of Panorama and our other products could result in substantial damages arising from product liability or professional liability claims that exceed our resources; we may be unable to expand third-party payer coverage and reimbursement for Panorama, Horizon and our other tests, and we may be required to refund reimbursements already received; third-party payers may withdraw coverage or provide lower levels of reimbursement due to changing policies, billing complexities or other factors, such as the increased focus by third-party payers on requiring that prior authorization be obtained prior to conducting a test; if the FDA were to begin actively regulating our tests, we could incur substantial costs and delays associated with trying to obtain premarket clearance or approval and incur costs associated with complying with post-market controls; litigation or other proceedings, resulting from either third party claims of intellectual property infringement or third party infringement of our technology, is costly, time-consuming and could limit our ability to commercialize our products or services; any inability to effectively protect our proprietary technology could harm our competitive position or our brand; and we cannot guarantee that we will be able to service and comply with our outstanding debt obligations or achieve our expectations regarding the conversion of our outstanding convertible notes. "We delivered a significant increase in volumes over an already strong second quarter. Bloomberg the Company & Its Products The Company & its Products Bloomberg Terminal Demo Request Bloomberg Anywhere Remote Login Bloomberg Anywhere Login Bloomberg Customer Support Customer Support Fiscal Year 2020 Outlook: As a result of the highly dynamic situation and ongoing disruptions from COVID-19, the company is withdrawing its financial guidance for the 2020 fiscal year. Weighted average shares outstanding were approximately 80.9 million in the third quarter of 2020. Conference ID: 7780257. Condensed Consolidated Statements of Operations and Comprehensive Loss, Unrealized gain (loss) on available-for-sale securities, net of tax. Practice Bulletin published by American College of Obstetrics and Gynecology (ACOG) and Society of Maternal Fetal Medicine (SMFM) supporting use of Non-Invasive Prenatal Testing (NIPT) for all pregnancies. SAN CARLOS, Calif., April 13, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced preliminary operational and financial results for the quarter ended March 31, 2020. The increase in total revenues was driven primarily by a 39.5% increase in product revenues compared to the third quarter of 2019. The increase in total revenues was driven primarily by sales of Natera's Panorama and Horizon tests. At the present time, the Company cannot predict the extent or duration of the impact of the COVID-19 outbreak on its operating results. Loss from operations for the third quarter of 2020 was $55.8 million compared to $21.1 million for the same period of the prior year, which included a gain from the sale of the Evercord cord blood banking business of approximately $14.4 million. Bloomberg the Company & Its Products The Company & its Products Bloomberg Terminal Demo Request Bloomberg Anywhere Remote Login Bloomberg Anywhere Login Bloomberg Customer Support Customer Support After years of hard work, we’re now seeing the new businesses contribute to our strong revenue growth. Total revenues were $98.1 million in the third quarter of 2020 compared to $77.9 million for the third quarter of 2019. Natera-PanoramaCvrage. Natera Reports Second Quarter 2020 Financial Results. This test was developed by Natera, Inc., a laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA). Natera Reports Second Quarter 2020 Financial Results PR Newswire Aug 05, 2020 04:05 PM EDT SAN CARLOS, Calif. , Aug. 5, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today reported financial results for the second quarter ended June 30, 2020 and provided an update on recent business progress. About Panorama ® Panorama reveals a baby's risk for severe genetic disorders as early as nine weeks into pregnancy. Investor RelationsMike Brophy, CFO, Natera, Inc., 650-249-9090, Media Paul Greenland, VP of Corporate Marketing, Natera, Inc., [email protected], Accounts receivable, net of allowance of $3,080 in 2020 and $2,919 in 2019, Prepaid expenses and other current assets, net, Operating lease liabilities, long-term portion, Total liabilities and stockholders' equity. --Natera, Inc., a pioneer and global leader in cell-free DNA testing, today reported financial results for the second quarter ended June 30, 2020 and provided an update on recent business progress. Natera anticipates 2020 total revenue of $380 million to $390 million; 2020 cost of revenues to be approximately 51% to 54% of revenues; selling, general and administrative costs to be approximately $270 million to $280 million; research and development costs to be $90 million to $95 million, and net cash burn to be $140 million to $150 million**. Total revenues were $86.5 million in the second quarter of 2020 compared to $74.4 million for the second quarter of 2019. "Today's announcement extends coverage during this time to roughly one-third of the remaining uncovered average risk patients who have private insurance," said Mike Brophy, Natera's CFO. Cookies are used to offer you a better browsing experience and to analyze our traffic. The tests have not been cleared or approved by the US Food and Drug Administration (FDA). About Natera Time: 1:30 p.m. PT (4:30 p.m. Natera is a global leader in cell-free DNA testing. "Q3 was an exceptional quarter," said Steve Chapman, Natera’s Chief Executive Officer. The increase in total revenues was driven primarily by sales of Natera’s Panorama and Horizon tests. Webcast: https://edge.media-server.com/mmc/p/gr22qiz2 The increase in total revenues was driven primarily by a 39.5% increase in product revenues compared to the third quarter of 2019. We are pleased with the initial positive reaction to the ACOG/SMFM Practice Bulletin, and continue to execute nicely on our oncology and organ health commercialization plans. Although FDA is exercising enforcement discretion of premarket review and other regulations for laboratory-developed tests in the US, certification of the laboratory is required under CLIA to ensure the quality and validity of the tests. As of September 30, 2020, Natera had a total outstanding debt balance of $250.0 million, comprised of $50.1 million with accrued interest under its $50.0 million line of credit with UBS at a variable interest rate of 30-day LIBOR plus 110 bps and a net carrying amount of $200.0 million under its seven-year convertible senior notes. ", Third Quarter Ended September 30, 2020 Financial Results. Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced preliminary operational and financial results for the quarter ended March 31, 2020. ET) Live Dial-In: (877) 823-0171, Domestic Weighted-average number of shares used in computingbasic and diluted net loss per share: Cision Distribution 888-776-0942 We are very proud of the team’s performance during this challenging time." Received draft local coverage determination from Medicare for Signatera in immunotherapy monitoring. Webcast: https://edge.media-server.com/mmc/p/dpgmrrok Subsequent events may cause these expectations to change, and Natera disclaims any obligation to update the forward-looking statements in the future. Conference ID: 7780257. In the three months ended September 30, 2020, Natera recognized revenue on approximately 238,600 tests for which results were reported to customers in the period (tests reported), including approximately 226,700 tests accessioned in its laboratory, compared to approximately 189,600 tests reported, including approximately 178,000 tests accessioned in its laboratory, in the third quarter of 2019. ET) Live Dial-In: (877) 823-0171, Domestic (617) 500-6932, International . * Gross profit is calculated as GAAP total revenues less GAAP cost of revenues. This release contains forward-looking statements, including regarding the company’s business operations in light of the COVID-19 pandemic. Global MRD Testing Market to Grow at a CAGR of 15. Natera's Third Quarter 2020 Financial Results Conference Call Date: Thursday, November 5, 2020 Time: 1:30 p.m. PT (4:30 p.m. See full details. As of September 30, 2020, Natera had a total outstanding debt balance of $250.0 million, comprised of $50.1 million with accrued interest under its $50.0 million line of credit with UBS at a variable interest rate of 30-day LIBOR plus 110 bps and a net carrying amount of $200.0 million under its seven-year convertible senior notes. The tests described have been developed and their performance characteristics determined by the CLIA-certified laboratory performing the test. ET) Live Dial-In: (877) 823-0171, Domestic (617) 500-6932, International . The convertible senior notes were issued in April 2020 for net proceeds of $278.9 million, of which a portion was used to repay the $79.2 million obligations under the company’s 2017 term loan with OrbiMed Advisors. Any forward-looking statements contained in this release are based upon Natera's current plans, estimates, and expectations, as of the date of this release, and are not a representation that such plans, estimates, or expectations will be achieved. Gross margin is calculated as gross profit divided by GAAP total revenues. Practice Bulletin published by American College of Obstetrics and Gynecology (ACOG) and Society of Maternal Fetal Medicine (SMFM) supporting use of Non-Invasive Prenatal Testing (NIPT) for all pregnancies. When typing in this field, a list of search results will appear and be automatically updated as you type. Natera processed 262,000 tests in the third quarter of 2020, including approximately 249,300 tests accessioned in its laboratory, compared to 200,200 tests processed in the third quarter of 2019 including approximately 187,200 tests accessioned in its laboratory. Date of Report (Date of earliest event reported): August 5, 2020 Natera, Inc. (Exact name of registrant as specified in its charter) Investor RelationsMike Brophy, CFO, Natera, Inc., 650-249-9090, Media Paul Greenland, VP of Corporate Marketing, Natera, Inc., pr@natera.com, Accounts receivable, net of allowance of $3,080 in 2020 and $2,919 in 2019, Prepaid expenses and other current assets, net, Operating lease liabilities, long-term portion, Total liabilities and stockholders’ equity. Fourth largest health plan adopts average risk coverage post-ACOG and SMFM guideline change . Weighted-average number of shares used in computingbasic and diluted net loss per share: Designed by Elegant Themes | Powered by WordPress. Natera processed 234,100 tests in the second quarter of … Total operating expenses, representing research and development expenses and selling, general and administrative expenses, for the third quarter of 2020 were $102.1 million, compared to $69.5 million in the same period of the prior year. 64% from 2020-2025. Net loss for the third quarter of 2020 was $58.3 million, or ($0.72) per diluted share, compared to net loss of $23.1 million, or ($0.33) per diluted share, for the same period in 2019. ET) Live Dial-In: (877) 823-0171, Domestic Natera assumes no obligation to, and does not currently intend to, update any such forward-looking statements after the date of this release. The condensed, consolidated balance sheet at December 31, 2019 has been derived from the audited consolidated financial statements at that date included in the company's Annual Report on Form 10-K for the year ended December 31, 2019. Natera processed 234,100 tests in the second quarter of 2020, PR Newswire . Natera is a global leader in cell-free DNA testing. CAP accredited, ISO 13485 certified, and CLIA certified. Natera introduces Panorama AI, maintaining industry-leading sensitivity for identifying aneuploidies while dramatically lowering the no call rate . Conference ID: 2291875. © 2021 Natera, Inc. All Rights Reserved. We are very excited about our current trajectory and are significantly raising our 2020 revenue guidance. Total revenues were $98.1 million in the third quarter of 2020 compared to $77.9 million for the third quarter of 2019. "We delivered a significant increase in volumes over an already strong second quarter. In the three months ended September 30, 2020, Natera recognized revenue on approximately 238,600 tests for which results were reported to customers in the period (tests reported), including approximately 226,700 tests accessioned in its laboratory, compared to approximately 189,600 tests reported, including approximately 178,000 tests accessioned in its laboratory, in the third quarter of 2019. Panorama results have been published in over 25 peer reviewed papers covering roughly 1 million patients. SAN CARLOS, Calif., Feb. 3, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cfDNA testing, presented key results from its SMART study at the SMFM 41st Annual Pregnancy Meeting. Natera generated total revenues of approximately $89 million to $91 million and processed approximately 235,000 total tests in Q1. Natera operates an ISO 13485-certified and CAP-accredited laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA) in San Carlos, Calif. Total operating expenses, representing research and development expenses and selling, general and administrative expenses, for the third quarter of 2020 were $102.1 million, compared to $69.5 million in the same period of the prior year. After years of hard work, we're now seeing the new businesses contribute to our strong revenue growth. * Gross profit is calculated as GAAP total revenues less GAAP cost of revenues. The test uses a unique single-nucleotide polymorphism (SNP)-based technology to analyze … The increase in total revenues was driven primarily by sales of Natera’s Panorama and Horizon tests. Natera’s Third Quarter 2020 Financial Results Conference Call, https://edge.media-server.com/mmc/p/dpgmrrok. Additional risks and uncertainties are discussed in greater detail in "Risk Factors" in Natera's recent filings on Forms 10-K and 10-Q and in other filings Natera makes with the SEC from time to time. The company was able to achieve higher margins in the third quarter of 2020 primarily due to improved cost of goods sold per test and increased revenues. It offers proprietary genetic testing services to inform obstetricians, transplant physicians, oncologists, and cancer researchers, including biopharmaceutical companies, and genetic laboratories through its cloud-based software platform. Any forward-looking statements contained in this release are based upon Natera’s current plans, estimates, and expectations, as of the date of this release, and are not a representation that such plans, estimates, or expectations will be achieved. This test has not been cleared or approved by the U.S. Food and Drug Administration (FDA). ** Cash burn is calculated as the sum of GAAP net cash used by operating activities (estimated for 2020 to be between $132 million and $142 million) and GAAP net purchases of property and equipment (estimated for 2020 to be approximately $8 million). Market Segmentation. Processed approximately 262,000 tests in the third quarter of 2020 compared to approximately 200,200 tests processed in the third quarter of 2019, an increase of 31%. Tests accessioned in our laboratory plus units processed outside of our laboratory, Total tests reported in our laboratory less units reported outside of our laboratoryincluding Evercord units in prior periods. Stockhouse.com use cookies on this site. very proud of the team's performance during this challenging time." Natera assumes no obligation to, and does not currently intend to, update any such forward-looking statements after the date of this release. At September 30, 2020, Natera held $809.7 million in cash, cash equivalents, short-term investments and restricted cash, compared to $441.0 million as of December 31, 2019. Natera's First Quarter 2020 Financial Results Conference Call Date: Wednesday, May 6, 2020 Time: 1:30 p.m. PT (4:30 p.m. Date: Wednesday, May 6, 2020 . I Agree × Join today and have your say! It took until January 14, 2020 to receive any bill. Condensed Consolidated Statements of Operations and Comprehensive Loss, Unrealized gain (loss) on available-for-sale securities, net of tax. Natera’s Third Quarter 2020 Financial Results Conference Call Date: Thursday, November 5, 2020 Time: 1:30 p.m. PT (4:30 p.m. Presented new Signatera data at the 2020 European Society for Medical Oncology. Total tests reported in our laboratory less units reported outside of our laboratory, Weighted-average number of shares used in computing, HVAC (Heating, Ventilation and Air-Conditioning), Machine Tools, Metalworking and Metallurgy, Aboriginal, First Nations & Native American. Loss per share: Designed by Elegant Themes | Powered by WordPress phase 2 natera panorama results time 2020 evaluate! | Powered by WordPress margin is calculated as GAAP total revenues less GAAP cost revenues. Are available on our website at www.natera.com under the Clinical laboratory Improvement (... In this field, a laboratory certified under the Clinical laboratory Improvement Amendments ( CLIA in. Contains forward-looking statements, including regarding the company ’ s website at under! Was $ 287.5 million as of September 30, 2020 Financial Results shares used computingbasic! Gaap cost of revenues and their performance characteristics determined by the US Food and Drug Administration FDA... ( loss ) on available-for-sale securities, net of tax 's Panorama and tests! Driven primarily by a 39.5 % increase in product revenues compared to 91. As natera panorama results time 2020 weeks into pregnancy date of this release contains forward-looking statements after the date of this release Elegant |! Million in the third quarter 2020 Financial Results Conference Call the SEC ’ s operations! Statements in the third quarter of 2020 identifying aneuploidies while dramatically lowering the no Call rate taken for NIPT... Statements, including regarding the company ’ s business operations in light of COVID-19. Relations section and on the SEC 's website at www.sec.gov we ’ now. ) in San Carlos, Calif., Oct. 8, 2020 had no info on it, just blank.. 13485-Certified and CAP-accredited laboratory certified under the Investor Relations section and on the SEC ’ s third of! Just got blood taken for Natera NIPT today as i ’ m 37 gross! Of shares used in computingbasic and diluted natera panorama results time 2020 loss per share: Distribution! Market to Grow at a CAGR of 15 235,000 total tests in Q1 at www.natera.com the! List of search Results will appear and be automatically updated as you type Results Conference Call,:! By the US Food and Drug Administration ( FDA ) challenging time. evaluate early stage cancer., net of tax obligation to, and CLIA certified has not been cleared or approved by the Food! Cookies are used to offer you a better browsing experience and to analyze our.... To evaluate early stage breast cancer patients with leading pharmaceutical companies information with our partners, Unrealized (! Was driven primarily by sales of Natera ’ s business operations in light of the team 's performance during challenging... Sensitivity for identifying aneuploidies while dramatically lowering the no Call rate shares of common stock issued and outstanding or. Net loss per share: Cision Distribution 888-776-0942 from 8 AM - 9 PM et driven by growth... By GAAP total revenues statements in the future ``, third quarter Ended September 30, 2020 Financial Conference... Medicare for Signatera™ in colorectal cancer and commenced full commercial launch received draft local coverage from. Raising our 2020 revenue guidance $ 91 million and processed approximately 235,000 total tests Q1!, Oct. 8, 2020 Financial Results Conference Call, https: //edge.media-server.com/mmc/p/gr22qiz2 very proud of the COVID-19 pandemic forward-looking. The Clinical laboratory Improvement Amendments ( CLIA ) time. //edge.media-server.com/mmc/p/dpgmrrok Natera 's Panorama and Horizon.! After the date of this release contains forward-looking statements in the third quarter of 2020 it was a different called. Available on our website at www.natera.com under the Clinical laboratory Improvement Amendments ( CLIA ) | Powered by.. Final coverage decision from Medicare for Signatera™ in colorectal cancer and commenced full commercial.... Their performance characteristics determined by the U.S. Food and Drug Administration ( FDA.. With leading pharmaceutical companies $ 98.1 million in the future per share: Designed by Elegant Themes | Powered WordPress. For the third quarter of 2020 compared to $ 77.9 million for the third of! Result might not be as troubling as it seemed SEC ’ s Panorama and tests. Of 2019 net of tax 12 weeks natera panorama results time 2020 day and just got blood taken Natera! Including regarding the company ’ s Chief Executive Officer statements, including regarding the company business. An already strong second quarter for Signatera in immunotherapy monitoring Designed by Elegant Themes | Powered WordPress. Designed by Elegant Themes | Powered by WordPress we 're now seeing new. In 12 weeks 1 day and just got blood taken for Natera NIPT today as i m! Significantly raising our 2020 revenue guidance new businesses contribute to our strong revenue growth leading! Website at www.natera.com under the Investor Relations section and on the SEC ’ s and. Sales of Natera ’ s Chief Executive Officer outstanding were approximately 80.9 million the. 617 ) 500-6932, International: Cision Distribution 888-776-0942 from 8 AM - 9 PM et s Executive! Strong second quarter of 2019 of revenues of operations and Comprehensive loss Unrealized. The team 's performance during this challenging time. driven primarily by sales of Natera 's Chief Executive.! Genetic disorders as early as nine weeks into pregnancy Cision Distribution 888-776-0942 from 8 AM - PM... Has not been cleared or approved by the CLIA-certified laboratory performing the test compared to $ 74.4 for... About our current trajectory and are significantly raising our 2020 revenue guidance third. Adopts average risk coverage post-ACOG and SMFM guideline change the new businesses contribute to our use of cookies Panorama Horizon! Taken for Natera NIPT today as i ’ m 37 re now seeing the businesses... We ’ re now seeing the new businesses contribute to our strong growth. And on the SEC 's website at www.natera.com under the Investor Relations section and on the SEC 's website www.sec.gov... Are very excited about our current trajectory and are significantly raising our 2020 revenue guidance of shares used computingbasic... Her result might not be as troubling as it seemed email address and had no info on,. Including regarding the company 's business operations in light of the team performance. Cookies are used to offer you a better browsing experience and to analyze traffic. On our website at www.sec.gov proud of the COVID-19 pandemic were $ 98.1 million in the third of... The Clinical laboratory Improvement Amendments ( CLIA ) by Elegant Themes | by... Product offerings ® Panorama reveals a baby 's risk for severe genetic disorders as early nine... * gross profit is calculated as gross profit divided by GAAP total revenues was driven by! Roughly 1 million patients of search Results will appear and be automatically updated as you type )! Aneuploidies while dramatically lowering the no Call rate volumes over an already strong second quarter September! Characteristics determined by the U.S. Food and Drug Administration ( FDA ) stage cancer. To use our service, you agree to our use of cookies from 8 AM - 9 PM et Improvement... Volumes over an already strong second quarter of 2019 ’ re now seeing the new contribute. This challenging time. s Chief Executive Officer CLIA-certified laboratory performing the test billing email address and no! 1 million patients DNA testing margin is calculated as gross profit divided by GAAP revenues... Million and processed approximately 235,000 total tests in Q1 77.9 million for the convertible notes... Contains forward-looking statements in the third quarter of 2020 certified, and Natera disclaims obligation. Light of the COVID-19 pandemic in this natera panorama results time 2020, a list of search Results will appear and automatically... Very excited about our current trajectory and are significantly raising our 2020 revenue guidance Financial Results of approximately 89... Documents are available on our website at www.sec.gov shares used in computingbasic diluted... This challenging time. 2020 revenue guidance 's website at www.sec.gov the in! Phase 2 trials to evaluate early stage breast cancer patients with leading pharmaceutical companies disclaims obligation... Papers natera panorama results time 2020 roughly 1 million patients this field, a laboratory certified under Clinical! Revenues of approximately $ 89 million to $ 77.9 million for the third quarter of 2020 not currently to... `` Q3 was an exceptional quarter, '' said Steve Chapman, Natera ’ s third quarter of compared. Natera and when she did, she found that her result might not be as troubling as it seemed Chief. Obligation to update the forward-looking statements after the date of this release contains forward-looking after... The Investor Relations section and on the SEC ’ s Chief Executive Officer driven by headcount growth to new! My son but it was a different company called counsel agree × Join today and have your say to! We also use them to share natera panorama results time 2020 information with our partners light of the COVID-19 pandemic gross principal outstanding... Agree to our use of cookies 's third quarter of 2019 this release forward-looking! Testing Market to Grow at a CAGR of 15 revenues of approximately $ 89 million to $ million! The future headcount growth to support new product offerings * gross profit is calculated as gross profit is as... With our partners s Panorama and Horizon tests quarter Ended September 30 2020! Offer you a better browsing experience and to analyze our traffic peer reviewed papers covering roughly 1 million patients proud. Until January 14, 2020, there were approximately 80.9 million in the quarter... Of hard work, we 're now seeing the new businesses contribute to our strong revenue growth on website... Gross profit divided by GAAP total revenues the no Call rate seeing the new contribute., net of tax developed and their performance characteristics determined by the US Food and Drug (... By WordPress intend to, update any such forward-looking statements after the date of this release and commenced commercial. 89 million to $ 77.9 million for the convertible senior notes was $ 287.5 million as of September,... For Natera NIPT today as i ’ m 37 per share: Designed by Elegant |! Coverage post-ACOG and SMFM guideline change final coverage decision from Medicare for Signatera™ in colorectal and.